MedTrace Logo

SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers

NCT02797236 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2018-04-11

No results posted yet for this study

Summary

This is a first-in-human, single-center, single-blinded, observer-masked randomized, dose escalation (two doses), placebo-controlled study in healthy volunteers.

Conditions

  • Shigellosis
  • Bacillary Dysentery

Interventions

BIOLOGICAL

SF2a-TT15 vaccine

BIOLOGICAL

SF2a-TT15 vaccine + adjuvant

BIOLOGICAL

Placebo

BIOLOGICAL

Placebo + adjuvant

Sponsors & Collaborators

  • Institut Pasteur

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02797236 on ClinicalTrials.gov